[go: up one dir, main page]

NO20022954D0 - Anvendelse av bioaktive metabolitter av gepiron for behandling av psykologiske forstyrrelser - Google Patents

Anvendelse av bioaktive metabolitter av gepiron for behandling av psykologiske forstyrrelser

Info

Publication number
NO20022954D0
NO20022954D0 NO20022954A NO20022954A NO20022954D0 NO 20022954 D0 NO20022954 D0 NO 20022954D0 NO 20022954 A NO20022954 A NO 20022954A NO 20022954 A NO20022954 A NO 20022954A NO 20022954 D0 NO20022954 D0 NO 20022954D0
Authority
NO
Norway
Prior art keywords
gepirone
psychological disorders
treatment
bioactive metabolites
metabolites
Prior art date
Application number
NO20022954A
Other languages
English (en)
Other versions
NO323304B1 (no
NO20022954L (no
Inventor
Stephen J Kramer
Louis F Fabre
Edward H Ruediger
Joseph P Yevich
Original Assignee
Joseph P Yevich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joseph P Yevich filed Critical Joseph P Yevich
Publication of NO20022954L publication Critical patent/NO20022954L/no
Publication of NO20022954D0 publication Critical patent/NO20022954D0/no
Publication of NO323304B1 publication Critical patent/NO323304B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20022954A 1999-12-20 2002-06-19 Anvendelse av bioaktive metabolitter av gepiron for fremstilling av et medikament for behandling av psykologiske forstyrrelser og farmasoytisk sammensetning omfattende samme NO323304B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17268499P 1999-12-20 1999-12-20
US09/709,741 US6534507B1 (en) 1999-12-20 2000-11-13 Methods for treating psychological disorders using bioactive metabolites of gepirone
PCT/US2000/034131 WO2001045687A2 (en) 1999-12-20 2000-12-18 Use of bioactive metabolites of gepirone for the treatment of psychological disorders

Publications (3)

Publication Number Publication Date
NO20022954L NO20022954L (no) 2002-06-19
NO20022954D0 true NO20022954D0 (no) 2002-06-19
NO323304B1 NO323304B1 (no) 2007-03-05

Family

ID=26868346

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022954A NO323304B1 (no) 1999-12-20 2002-06-19 Anvendelse av bioaktive metabolitter av gepiron for fremstilling av et medikament for behandling av psykologiske forstyrrelser og farmasoytisk sammensetning omfattende samme

Country Status (20)

Country Link
US (1) US6534507B1 (no)
EP (1) EP1242061B1 (no)
JP (1) JP4236407B2 (no)
KR (1) KR100602976B1 (no)
CN (1) CN1411375A (no)
AT (1) ATE294572T1 (no)
AU (1) AU776409B2 (no)
CA (1) CA2395458C (no)
CZ (1) CZ300429B6 (no)
DE (1) DE60019968T2 (no)
ES (1) ES2241683T3 (no)
HU (1) HU228963B1 (no)
IL (2) IL150222A0 (no)
MX (1) MXPA02006146A (no)
NO (1) NO323304B1 (no)
NZ (1) NZ519554A (no)
PL (1) PL200378B1 (no)
PT (1) PT1242061E (no)
RU (1) RU2282448C2 (no)
WO (1) WO2001045687A2 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016347A1 (en) * 2000-08-22 2002-02-28 Akzo Nobel N.V. Active metabolite of gepirone
US20040002500A1 (en) * 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
US20040000689A1 (en) * 2002-06-28 2004-01-01 Erh-Kun Lai Dual-bit MONOS/SONOS memory structure with non-continuous floating gate
AU2003259086A1 (en) * 2002-08-12 2004-02-25 Bristol-Myers Squibb Company Improved process for hydroxyazapirones
US20050004105A1 (en) * 2003-01-29 2005-01-06 Emer Leahy Treatment for a attention-deficit hyperactivity disorder
TW200521125A (en) * 2003-11-18 2005-07-01 Bristol Myers Squibb Co Continuous process for producing hydroxyazapirones by oxidation
EA013213B1 (ru) * 2004-11-05 2010-04-30 Фэйбр-Крэймер Холдингз, Инк. Дозированная форма биоактивного метаболита гепирона с высокой дозировкой и длительным высвобождением, способ ее получения и способ лечения депрессии с ее использованием
BRPI0912516A2 (pt) * 2008-05-08 2015-10-13 Fabre Kramer Pharmaceuticals Inc 3-hidróxi gepirona para o tratamento de distúrbio de défict de atenção e disfunção sexual

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4423049A (en) 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
US5185329A (en) * 1988-08-30 1993-02-09 Bristol-Myers Squibb Company Method for treatment of substance addiction
CA2051399C (en) * 1989-05-31 2003-12-30 Chiu-Hong Lin Therapeutically useful 2-aminotetralin derivatives
US4956368A (en) 1989-07-24 1990-09-11 Bristol-Myers Company Metabolites and prodrug formulations of 8-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form

Also Published As

Publication number Publication date
EP1242061A2 (en) 2002-09-25
DE60019968D1 (de) 2005-06-09
JP2004500362A (ja) 2004-01-08
MXPA02006146A (es) 2004-08-23
JP4236407B2 (ja) 2009-03-11
ES2241683T3 (es) 2005-11-01
HUP0301831A2 (hu) 2003-09-29
KR100602976B1 (ko) 2006-07-20
IL150222A0 (en) 2002-12-01
ATE294572T1 (de) 2005-05-15
WO2001045687A2 (en) 2001-06-28
NO323304B1 (no) 2007-03-05
KR20020082470A (ko) 2002-10-31
CA2395458A1 (en) 2001-06-28
RU2282448C2 (ru) 2006-08-27
IL150222A (en) 2009-09-22
AU2268701A (en) 2001-07-03
AU776409B2 (en) 2004-09-09
PL364936A1 (en) 2004-12-27
PL200378B1 (pl) 2008-12-31
PT1242061E (pt) 2005-09-30
WO2001045687A3 (en) 2002-04-25
DE60019968T2 (de) 2006-02-02
US6534507B1 (en) 2003-03-18
NZ519554A (en) 2005-01-28
NO20022954L (no) 2002-06-19
CN1411375A (zh) 2003-04-16
RU2002119400A (ru) 2004-01-27
CA2395458C (en) 2009-05-12
CZ300429B6 (cs) 2009-05-20
EP1242061B1 (en) 2005-05-04
CZ20022137A3 (cs) 2003-03-12
HU228963B1 (en) 2013-07-29

Similar Documents

Publication Publication Date Title
AR027528A1 (es) Preparacion farmaceutica para el tratamiento de rinitis alergica y/o vasomotriz o conjuntivitis alergica, la utilizacion de dicha preparacion para laobtencion de medicamentos y el procedimiento para preparar dichos medicamentos
MXPA04002825A (es) Derivados de quinolina como antagonistas de neuropeptido y.
RU2003114752A (ru) Лечение желудочно-кишечных стромальных опухолей
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
NO20052927L (no) 2,4,6-trisubstituerte pyrimidiner av fosfotidylinositol (PI) 3-kinaseinhibitorer og deres anvendelse ved behandling av kreft
WO2003004480A3 (en) Substituted piperazine and diazepanes as histamine h3 receptor agonists
ATE402176T1 (de) Pyrrolidin- und azetidinverbindungen alsccr5- antagonisten
SI1185272T1 (en) Novel use of 1-(4-(5-cyanoindol-3yl)butyl)-4-(2-carbamoylbenzofuran-5-yl)piperazine and its physiological acceptable salts for the treatment of bipolar disorders and mania
AU2003300911A1 (en) Heterocyclic compounds as ccr5 antagonists
NO20022954D0 (no) Anvendelse av bioaktive metabolitter av gepiron for behandling av psykologiske forstyrrelser
NZ594369A (en) Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases
BR0209103A (pt) Omeprazol forma c, processo para preparação e uso do mesmo e formulação farmacêutica
MD523G2 (ro) Derivaţi noi ai triazolpirimidinei, antagonişti ai receptorilor angiotensinei II, procedee de preparare a lor, compoziţii farmaceutice ce le conţin
AR015966A1 (es) Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
LV10268A (lv) Terapeitiski aktivs benzimidazols un ta iegusanas panemiens
EP1256344A4 (en) REMEDIES FOR ENDOTHELIN-INDUCED DISEASES
RU2002118304A (ru) Способ подавления чувства страха
PE20011004A1 (es) Composicion de liberacion controlada de un inhibidor de fosfodiesterasa 4
ATE389655T1 (de) Pyrimidinderivate
KR960700696A (ko) 정맥성 질환 치료에 유용한 5-하이드록시트립타민-2 수용체 길항물질 조성물(5-ht₂receptor antagonist compositions useful in treating venous conditions)
CA2364178A1 (en) N-benzenesulfonyl l-proline compounds as bradykinin antagonists
ES2089974A1 (es) Utilizacion de los derivados de 1-(4-)4-aril (o heteroaril)-1-piperazinil)-butil)-1-h-azol para la preparacion de medicamentos destinados al tratamiento de los trastornos de la secrecion gastrica.
ES2076894A1 (es) Derivados de 2-(4-(4-azolibutil)-1-piperacinil)-5-hidroxipirimidina, su preparacion y su aplicacion como medicamentos.
DE50312523D1 (de) Pharmazeutische wirkstoffkombination sowie deren verwendung
AU2173101A (en) Use of carboxy compounds such as 2(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride as anti-inflammatory agents

Legal Events

Date Code Title Description
MK1K Patent expired